Is Ketamine Microdosing?

Strictly speaking, no, ketamine therapy is not "microdosing," because a microdose by definition is one you do not perceive, and therapeutic ketamine doses are felt. But that is a vocabulary mismatch, not a red flag. The concern hiding inside the question is usually about frequency: people have heard ketamine can harm the bladder, so taking it regularly sounds risky. The honest, evidence-based answer is that supervised low-dose ketamine, including frequent or daily dosing, has a good safety profile, and the serious harms are a feature of high-dose recreational use, not therapeutic dosing.

Microdosing is a classic-psychedelic concept: a fraction of a recreational dose of something like psilocybin or LSD, low enough to be sub-perceptual, taken every few days. If you can feel it, it is not a microdose. And the research on whether psychedelic microdosing produces real benefits remains genuinely unsettled.¹

Therapeutic ketamine does not fit that definition, because feeling the gentle dissociative, introspective effect is part of how it is understood to work. So "microdosing" is just an imprecise label some clinics borrowed. It does not describe the pharmacology, and it does not imply anything about safety one way or the other.

Yes, under medical supervision, and this is the part the scarier framing gets wrong. Low-dose ketamine has a long track record in chronic pain, where ongoing regimens, including daily and sometimes more frequent dosing, are used and studied.²,³ Frequency by itself is not the hazard. A controlled therapeutic dose taken regularly under monitoring is a different thing from escalating recreational use.

In practice, plenty of patients do well on regular low-dose schedules. What makes that safe is not rarity of dosing, it is that the dose is controlled, the patient is monitored, and the regimen is adjusted to the individual.

Ketamine cystitis is real and worth respecting, but its context matters. The serious bladder and urinary-tract damage reported in the literature is overwhelmingly tied to chronic, heavy recreational use, where people consume doses far higher and far more often than any therapeutic regimen.⁴,⁵ These effects are dose- and frequency-dependent, which is exactly why supervised low-dose use sits in a different risk category.

At therapeutic doses, bladder problems are uncommon. And the safeguard is straightforward: monitor for early urinary symptoms (urgency, frequency, discomfort), and if they appear, reduce the dose or pause. Caught early, the symptoms typically improve when dosing is lowered or stopped. Monitoring, not avoidance of regular dosing, is the right tool.

The same logic applies. Ketamine has genuine abuse and dependence potential, but that potential is realized at recreational doses and patterns of use, well above what supervised therapy involves. Used at therapeutic doses within a monitored plan, that risk is far lower. The distinction, again, is dose and oversight, not frequency in the abstract.

In a legitimate program, your dose is calibrated to you, your schedule is set by a physician, and you are monitored over time, including for urinary symptoms if you are on a regular regimen. If something looks off, the plan changes. That structure is what separates safe ongoing therapeutic use from the recreational pattern that generates the alarming headlines. The word "microdosing" is beside the point. What protects you is the dose and the supervision.